Aurinia Pharmaceuticals Reports Strong Q3 Growth, Enhances Autoimmune Disease Treatment Strategy

Aurinia Pharmaceuticals Strengthens Position in Autoimmune Disease Treatment

Aurinia Pharmaceuticals Inc. showcases its robust financial performance for the third quarter of 2024, reflecting a strategic focus on enhancing its commercial strategy and pipeline development. The company reports total net revenue of $67.8 million for Q3, marking a substantial 24% increase compared to $54.5 million in the same period last year. Over the first nine months of 2024, Aurinia achieves total net revenue of $175.3 million, a significant jump from $130.4 million in the previous year. With net product revenue reaching $158.6 million, Aurinia forecasts that its net product revenue for the fiscal year will range between $210 and $220 million, positioning the company for continued growth in the autoimmune disease sector.

Aurinia’s strategic restructuring entails a workforce reduction of approximately 45%, aimed at maximizing the impact of its flagship product, LUPKYNIS®, while accelerating the development of AUR200. This move is projected to generate over $40 million in annualized cash-based operating expense savings. In the third quarter, Aurinia successfully expands its reach by adding 364 provider sites and enrolling 146 new patients, bringing the total number of patients on LUPKYNIS® to 510—an increase of 17% year-over-year. The company also makes significant strides in its pipeline, initiating a Phase 1 study for AUR200, a promising therapy targeting autoimmune diseases, with initial results anticipated in the first half of 2025.

The recent approval of LUPKYNIS® by the Japanese Ministry of Health further bolsters Aurinia’s commercial strategy, resulting in a $10 million milestone payment from Otsuka Pharmaceutical Co., Ltd. This development underscores Aurinia's commitment to addressing unmet medical needs in the autoimmune space. CEO Peter Greenleaf expresses optimism regarding the company's streamlined focus, which aims to maximize returns from LUPKYNIS® while advancing its innovative pipeline. By investing in its future through strategic leadership changes and targeted therapies, Aurinia affirms its dedication to improving health outcomes for patients with autoimmune diseases.

In an important governance update, Aurinia Pharmaceuticals announces the appointment of Craig Johnson to its Board of Directors, bringing over 30 years of financial management experience in the biotechnology sector. This leadership transition comes as Dr. Robert T. Foster retires from the Board, with Kevin Tang, the Chair of the Board, expressing gratitude for Foster's contributions and welcoming Johnson's expertise. This addition is expected to enhance Aurinia's capacity to navigate its next phase of growth while maintaining a strong commitment to delivering innovative therapies for patients in need.